arrow
毕焱 封面图

毕焱 (Yan Bi)

Nanjing Drum Tower Hospital邮箱:biyan@nju.edu.cn
H指数:38
被引数:6,731

个人简介

"2016年于郑州大学获理学学士学位,2021年于同济大学获理学博士学位,2021至2024年在同济大学生命科学与技术学院生物医学工程流动站从事博士后研究。2024年3月起受聘与同济大学生命科学与技术学院。\n主要研究方向为人多能性细胞命运调控及类胚胎研究。主要研究成果包括鉴定出首个原态细胞特异地功能性表面标志物蛋白;\n建立基因组稳定性更优的原态诱导培养体系;首次追溯并描绘了人始发态向原态多能性转变过程中的细胞亚群命运转变动态图谱,首次利用始发态向原态转变过程中特定时间点的中间态细胞群体建立人类囊胚模型,并实现人原肠胚前发育模拟;并从细胞通讯角度解析人胚胎细胞命运调控机理。相关成果发表已发表于Nature Communications, Cell Research, Science Bulletin, Protein & Cell(2023,2025), Cell Reports、Cell Regeneration等杂志,目前申请国家发明专利8项,已获得授权1项,主持国家自然科学基金面上项目两项(2023,2025),青年项目一项(2021),参与重点科技部重点研发项目一项(骨干,2023),入选上海市晨光计划(2024),获得博士后“上海市日常资助”。\n发表文章\n1. Bi Y*#, Hu J*, Wu T*, Ouyang Z, Lin T, Sun J, Zhang X, Xu X, Wang H, Wei K, Gao S#, Wang Y#. Optimized derivation and culture system of human naïve pluripotent stem cells with enhanced DNA methylation status and genomic stability. Protein Cell 2025, 10.1093/procel/pwaf053.\n2. Tu Z, Bi Y*#, Lin T, Wu T, Wang H, Li J, Huang G, Gao S#, and Wang Y#. Intercellular crosstalk within human preimplantation lineages regulates trophectoderm specification. Science Bulletin 2025,10.1016/j.scib.2025.06.003.\n3. Liu K*, Yan Z*, Bai D*, J Rui*, Bi Y*, Ma X* et al., Modeling post-gastrula development via bidirectional pluripotent stem cells, Cell Research, 2025\n4. Tu Z*, Bi Y*, Zhu X, Liu W, Hu J, Wu L, Mao T, Zhou J, Wang H, Wang H et al: Modeling human pregastrulation development by 3D culture of blastoids generated from primed-to-naive transitioning intermediates. Protein Cell 2023, 14(5):337-349.\n5. Tu Z*, Bi Y*, Mao T*, Wang H, Gao S, Wang Y: Discordance between chromatin accessibility and transcriptional activity during the human primed-to-naive pluripotency transition process. Cell Regen 2023, 12(1):35.\n6. Bi Y*, Tu Z*, Zhou J, Zhu X, Wang H, Gao S, Wang Y: Cell fate roadmap of human primed-to-naive transition reveals preimplantation cell lineage signatures. Nature Communications 2022, 13(1).\n7. Bi Y*, Tu Z*, Zhang Y, Yang P, Guo M, Zhu X, Zhao C, Zhou J, Wang H, Wang Y et al: Identification of ALPPL2 as a Naive Pluripotent State-Specific Surface Protein Essential for Human Naive Pluripotency Regulation. Cell Rep 2020, 30(11):3917-3931 e3915."

教育背景

  • 2016.12

    郑州大学 理学学士

  • 2021.12

    同济大学 理学博士

工作经历

  • 2024.03 – 至今

    同济大学生命科学与技术学院

  • 2021.01 – 2024.12

    同济大学生命科学与技术学院生物医学工程流动站

    博士后

荣誉奖项

  1. 上海市晨光计划(2024)
  2. 上海市日常资助
Associations of four triglyceride-related metabolic surrogate indices with heart rate variability and confirmed cardiovascular autonomic neuropathy in type 2 diabetes: a cross-sectional study

四种甘油三酯相关代谢替代指标与心率变异性及2型糖尿病中确诊的心血管自主神经病变的关系:一项横断面研究

2026-11-050
OAAI
Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)

成人2型糖尿病的三联口服药物治疗(含二甲双胍、DPP-4抑制剂和SGLT2抑制剂):中国专家共识(2025年版)

2025-10-140
OAAI
Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study

达格列净恢复了2型糖尿病患者的嗅觉诱发性初级嗅觉皮层回路的机能整合,但并未恢复嗅觉相关区域的大脑激活:一项16周的随机比较研究

2025-09-150
OAAI